Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Neil Donald Merrett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8370-0293; OpenAlex author ID A5045066173. Sources: OpenAlex.

Their work

Papers
36 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: none · 2015: 3 papers · 2016: 6 papers · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 4 papers · 2023: 3 papers · 2024: none · 2025: 3 papers

Papers 36

  1. Aiming for high quality of care for completed resections and improved margin status in pancreatic cancer surgery. Co-author DOI 10.1016/j.pan.2025.09.029↗
  2. Association between volume and cost in low-resection volume regions: a population-level study on pancreatoduodenectomy for pancreatic cancer patients. Co-author DOI 10.1111/ans.19273↗
  3. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  4. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  5. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  6. The Unmet Needs of Pancreatic Cancer Carers Are Associated with Anxiety and Depression in Patients and Carers. Co-author DOI 10.3390/cancers15225307↗
  7. The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2021.11.005↗
  8. Prognostic models to predict survival in patients with pancreatic cancer: a systematic review. Co-author DOI 10.1016/j.hpb.2022.01.011↗
  9. Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. Co-author DOI 10.1038/s41416-022-01752-3↗
  10. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  11. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. Co-author DOI 10.1111/ans.17151↗
  12. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  13. Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review. Co-author DOI 10.1016/j.hpb.2019.09.002↗
  14. Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based … Co-author DOI 10.1016/j.pan.2020.07.405↗
  15. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  16. Port-site metastasis of pancreatic adenocarcinoma following 'successful' completion of neoadjuvant chemoradiation using FOLFIRINOX. Last author DOI 10.1111/ans.15441↗
  17. Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. Co-author DOI 10.1371/journal.pone.0243312↗
  18. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. Co-author DOI 10.1016/j.hpb.2018.08.016↗
  19. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  20. Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes. Co-author DOI 10.1017/s1478951517000608↗
  21. Biliary Stenting in Patients With Pancreatic Cancer: Results From a Population-Based Cohort Study. Co-author DOI 10.1097/mpa.0000000000000960↗
  22. Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. Co-author DOI 10.1111/ajco.12862↗
  23. Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Co-author DOI 10.1016/j.pan.2017.01.008↗
  24. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  25. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Co-author DOI 10.18632/oncotarget.20822↗
  26. Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. Co-author DOI 10.1007/s00520-016-3212-4↗
  27. Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. Co-author DOI 10.1007/s11605-016-3157-4↗
  28. Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. Co-author DOI 10.1016/j.pan.2016.06.010↗
  29. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  30. Using a Delphi process to determine optimal care for patients with pancreatic cancer. Co-author DOI 10.1111/ajco.12450↗
  31. Factors associated with quality of care for patients with pancreatic cancer in Australia. Co-author DOI 10.5694/mja16.00567↗
  32. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Co-author DOI 10.1002/bjs.9892↗
  33. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  34. Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1097/mpa.0000000000000384↗
  35. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  36. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Co-author DOI 10.1093/annonc/mdr561↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rachel Ε. Neale · 18 shared papers, 2015–2025 · strength 1.62
  2. David Goldstein · 14 shared papers, 2015–2020 · strength 0.98
  3. Elizabeth A. Burmeister · 11 shared papers, 2015–2022 · strength 0.85
  4. Sue Evans · 7 shared papers, 2019–2025 · strength 0.82
  5. Helen M. Gooden · 11 shared papers, 2015–2023 · strength 0.80
  6. Monika Janda · 11 shared papers, 2015–2023 · strength 0.80
  7. Vanessa L. Beesley · 11 shared papers, 2015–2023 · strength 0.80
  8. James G. Kench · 8 shared papers, 2012–2025 · strength 0.75
  9. Ashika D. Maharaj · 6 shared papers, 2019–2025 · strength 0.70
  10. John Raymond Zalcberg · 6 shared papers, 2019–2025 · strength 0.70
  11. Liane Ioannou · 6 shared papers, 2019–2025 · strength 0.70
  12. Charles H. C. Pilgrim · 6 shared papers, 2019–2025 · strength 0.70
  13. Kate White · 6 shared papers, 2019–2025 · strength 0.70
  14. Daniel Gerald Croagh · 6 shared papers, 2019–2025 · strength 0.70
  15. David Goldstein · 5 shared papers, 2015–2025 · strength 0.57
  16. Jaswinder Singh Samra · 6 shared papers, 2012–2025 · strength 0.55
  17. Mary A. Waterhouse · 5 shared papers, 2016–2020 · strength 0.37
  18. Jennifer A. M. Philip · 4 shared papers, 2019–2022 · strength 0.36
  19. Trevor Leong · 3 shared papers, 2020–2022 · strength 0.29
  20. Koroush Shahsavar Haghighi · 2 shared papers, 2019–2025 · strength 0.27
  21. Vincent W. T. Lam · 1 shared paper, 2025 · strength 0.27
  22. Ling Li · 1 shared paper, 2025 · strength 0.27
  23. Madeleine E. Payne · 4 shared papers, 2015–2018 · strength 0.24
  24. Charbel Sandroussi · 2 shared papers, 2019–2021 · strength 0.20
  25. Thi N. T. Huynh · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.